| Manufacturer |
Novo Nordisk |
Novo Nordisk |
| Pricing |
Manufacturer self-pay offers:
- Introductory Offer: $199/month for the first two months of eligible new injection prescriptions at 0.25 mg or 0.5 mg.
- Standard Injection Offers: $349/month for 0.25 mg, 0.5 mg, or 1 mg; $499/month for 2 mg.
- Oral Formulation: Manufacturer self-pay offers start at $149/month, depending on dosage and eligibility.
Retail prices may be higher. |
Manufacturer self-pay offers:
- Introductory Injection Offer: $199/month for the first two months of eligible new prescriptions at 0.25 mg or 0.5 mg.
- Standard Injection Offers: $349/month for doses through 2.4 mg; $399/month for Wegovy HD 7.2 mg.
- Oral Formulation: $149/month for 1.5 mg, $199/month for 4 mg, and $299/month for 9 mg or 25 mg through eligible self-pay programs.
Retail prices may be higher. |
| Insurance Coverage |
- Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for medically eligible beneficiaries.
- Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
|
- Commercial Insurance: Some plans cover Wegovy for eligible patients with obesity, overweight, or other approved indications.
- Prior Authorization: Medical eligibility, BMI documentation, and supporting health information may be required.
- Medicare: Certain beneficiaries may qualify for covered indications or the Medicare GLP-1 Bridge program, subject to eligibility and plan requirements.
- Savings Programs: Eligible commercially insured patients may pay as little as $25/month.
|
| Main Purpose |
Improve blood sugar control in adults with type 2 diabetes. |
Long-term weight loss and weight maintenance in eligible patients with obesity or overweight and qualifying weight-related conditions. |
| Secondary Purposes |
- Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes.
- Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
|
- Cardiovascular Protection: Reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
- Liver Health: Wegovy injections are approved for certain adults with MASH and moderate to advanced liver fibrosis.
- Adolescent Weight Management: Wegovy injections are approved for adolescents aged 12 and older with obesity.
|
| Active Ingredient |
Semaglutide, a GLP-1 receptor agonist. |
Semaglutide, a GLP-1 receptor agonist. The same active ingredient as Ozempic. |
| Benefits |
- Blood Sugar Control: Lowers blood glucose and HbA1c.
- Weight Management: May promote weight loss.
- Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
- Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
|
- Weight Loss: Produces substantial average weight reduction in eligible patients.
- Appetite Regulation: Helps reduce hunger and food intake.
- Cardiovascular Health: Reduces major cardiovascular events in eligible adults with established cardiovascular disease.
- Liver Health: May improve MASH and liver fibrosis outcomes in the approved adult population when using the indicated injectable formulation.
|
| Potential Health Risks |
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Possible worsening of diabetic retinopathy.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Diabetic retinopathy complications may occur in patients with diabetes.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential |
Can produce clinically meaningful weight loss, but results depend on dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. |
Wegovy 2.4 mg injections produced approximately 15% average weight loss after 68 weeks in a major trial involving adults without diabetes. Wegovy 25 mg tablets also demonstrated substantial weight loss in clinical trials. Results vary by formulation, dose, and patient population. |
| Administration |
- Injection: Subcutaneous injection once weekly.
- Oral Tablet: Once-daily oral formulation with specific administration instructions.
|
- Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Oral Tablet: Once-daily tablet taken on an empty stomach with water, followed by at least 30 minutes before food, beverages, or other oral medications.
|
| Dosing Considerations |
- Starting Injection Dose: Typically 0.25 mg weekly.
- Dose Escalation: Gradual increases based on treatment response and tolerability.
- Maximum Injection Dose: 2 mg weekly for adults.
- Oral Dosing: Follows a separate daily dosing schedule.
|
- Starting Injection Dose: Typically 0.25 mg weekly.
- Injection Maintenance Doses: Commonly 1.7 mg or 2.4 mg weekly, with Wegovy HD 7.2 mg available for eligible adults.
- Oral Starting Dose: 1.5 mg once daily, followed by gradual dose escalation.
- Oral Maintenance Dose: 25 mg once daily for approved adult weight-management and cardiovascular indications.
|
| Who May Benefit Most? |
Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications. |
Adults with obesity or qualifying overweight who need long-term weight management; adolescents aged 12 and older with obesity who qualify for injections; and adults who meet its cardiovascular or MASH treatment indications. |
| How Fast Does It Work? |
- Blood Sugar: Improvements may begin within the first weeks.
- HbA1c: Reductions are generally assessed over approximately 3 months.
- Weight Loss: Typically develops gradually over several months.
|
- Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within the first several weeks.
- Substantial Weight Loss: Generally develops over several months, with major clinical trials evaluating outcomes over approximately 64–68 weeks or longer.
|
| Potential Side Effects |
- Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
|
- Digestive: Nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion.
- Other Effects: Headache, fatigue, dizziness, and possible injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
|